Vijaya Sivalingam Ramalingam, MD
Pulmonary Disease · Gainesville, GANPI 1871724872
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 68.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $2,433 and has fallen 91.6% since, to $204 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 45 payments — averaging $90.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Olympus Corporation Of The Americas$576
- GSK$333
- United Therapeutics Corporation$269
- Grifols USA, LLC$48
- AstraZeneca$37
- plus $32 from 2 others
Across 4 payments — averaging $11,422 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$46K
What the payments were for
- Speaking & faculty fees$2,23055%
- Travel & lodging$57614%
- Food & beverage$1,25931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $2,769 |
| Olympus Corporation Of The Americas | 4 | $576 |
| GSK | 20 | $333 |
| United Therapeutics Corporation | 3 | $269 |
| Grifols USA, LLC | 2 | $48 |
| AstraZeneca | 2 | $37 |
| CSL Behring | 1 | $20 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINGLE USE SUCTION VALVE (Sterile)$571
- Olympus$369
- TYVASO$248
- OFEV$120
How this compares
$4,065 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $307,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 238 | $168,744 |
| XembifyImmune Globulin,gamma(Igg)klhw | 26 | $104,050 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $35,608 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $30,967 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,205 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,839 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 17 | $5,386 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $2,806 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,604 |
| Mycophenolate Mofetil | 13 | $1,476 |
| Ventolin HfaAlbuterol Sulfate | 17 | $930 |
| Ipratropium Bromide | 15 | $441 |
| Fluticasone Propionate | 23 | $348 |
| Montelukast Sodium | 14 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $2,769 | $307,50024 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arexvy | $333 | $222,141361 claims |
| Grifols USA, LLCXembify | $48 | $104,05026 claims |
| AstraZenecaBreztri Aerosphere | $37 | $35,60853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Gainesville
- Vivek SambharaGainesville$417K
- Lawrence McDermottSavannah$963K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.